Mohamad Mohty, Professor of Hematology at Sorbonne University and head of the Clinical Hematology and Cellular Therapy Department at Saint-Antoine Hospital, reshared a post on X by Uriel Suárez, Resident of hematology at Jiménez Díaz Foundation University Hospital, adding:
“COMMAND is the largest randomized trial in MDS, and now we have long-term follow-up presented by Gullermo Garcia-Manero at ASH24 EPO/ESA clearly needs to retire very quickly.
Luspatercept works in ALL subgroups irrespective of the ring sideroblasts status. The field is finally entering into a modern era.
Luspa is an incredible example on the transfer of scientific discoveries to the bedside (it is a recombinant fusion protein that binds TGF β superfamily ligands to reduce SMAD2 and SMAD3 signaling).”
Quoting Uriel Suárez’s post:
“ASH24. Long-term response analysis of transfusion independence in ESA–naive patients with very low-, low-, or intermediate-risk MDS treated with Luspatercept Vs Epoetin Alfa in the COMMANDS Trial.”
More posts featuring Mohamad Mohty.